TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Citius Pharmaceuticals ( (CTXR) ) has issued an update.
On December 1, 2025, Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, announced the commercial launch of LYMPHIR™, a novel IL-2 receptor-directed fusion protein. This product, approved by the FDA, is designed for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy. The launch marks a significant milestone for Citius Oncology as LYMPHIR is their first marketed product, potentially impacting the company’s market position and providing growth opportunities in the estimated $400 million U.S. market for this condition.
The most recent analyst rating on (CTXR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.
Spark’s Take on CTXR Stock
According to Spark, TipRanks’ AI Analyst, CTXR is a Underperform.
Citius Pharmaceuticals’ overall stock score reflects the challenging financial performance and bearish technical indicators. The company’s ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock’s downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.
To see Spark’s full report on CTXR stock, click here.
More about Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing innovative targeted oncology therapies. The company operates through its majority-owned subsidiary, Citius Oncology, Inc., which has been a stand-alone public company since August 2024. Citius Oncology’s mission is to deliver innovative, targeted oncology therapies that transform patient outcomes, with a focus on the U.S. market.
Average Trading Volume: 788,520
Technical Sentiment Signal: Sell
Current Market Cap: $26.6M
For a thorough assessment of CTXR stock, go to TipRanks’ Stock Analysis page.